Drug Approval | May 07, 2026
Venus Remedies gets marketing authorization for Ceftriaxone in Argentina
Approval strengthens the company’s growing international anti-infective portfolio
Approval strengthens the company’s growing international anti-infective portfolio
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
Venus Remedies now has 29 active product approvals in Vietnam alone
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Initiative aimed at enhancing workforce skills and competency in line with industry standards so as to create a talented workforce for the Fourth Industrial Revolution
Subscribe To Our Newsletter & Stay Updated
